Selling a Medical Device Manufacturing Business: the architecture of a premium exit
The medical device manufacturing owner-CEOs commanding the top multiples in this market are not the most profitable. They are the most transferable. Profitability is necessary. Transferability is what makes the difference between Gross Enterprise Value and Transferable Value.
The two numbers every medical device mfg owner should know
The first number is the Gross Enterprise Value: revenue or EBITDA multiplied by the top multiple your sector commands. For medical device manufacturing, that's typically 14x on TTM EBITDA at the high end of 15–25% margins.
The second number is the Transferable Value: the post-due-diligence M&A price, calculated net of the company-specific risk a sophisticated buyer will surface. The gap between the two is the Value Gap, and in the medical device manufacturing segment, it is structurally driven by the five concerns below.
What suppresses Transferable Value in this category
- ISO 13485 audit history and 483 / warning letter exposure
- Customer concentration in medical device OEMs
- FDA registration and device classification clarity
- QSR (21 CFR 820) compliance posture
- Design history file (DHF) and document control maturity
The Battle-Ready Index, applied to your sale
The Battle-Ready Index™ is the scored diagnostic the most disciplined acquirers in medical device manufacturing are increasingly using to price the substrate underneath your EBITDA. Six factors. Each scored 0–100. In your category, the binding factor is typically Architecture:
Bench
Leadership depth and succession readiness without founder dependency.
Architecture · most exposed in this industry
Operating systems, governance, decision rights, financial reporting discipline.
Transferability
Knowledge, customer relationships, and IP owned by the business, not by individuals.
Tempo
Operating cadence, financial discipline, reporting rhythm.
Loyalty
Retention, culture, and succession stickiness through ownership change.
Endurance
Pressure-tested capacity to absorb ownership change and scale demand.
The 18-month architecture toward a premium exit
Sellers who reach the Asset Class threshold (Strategic Capacity Score 85+) before going to market consistently command the upper end of the 14x multiple band, and often above it. The path is structural, not narrative:
- Months 1–3 · Position & Read. Strategic Capacity score baseline. Value Gap quantification. Substrate read. The first deliverable is honest information about where you stand.
- Months 4–9 · Install. Organizational structural integrity. Decision rights, governance, financial reporting discipline, SOPs. Founder dependency reduction is the core work.
- Months 10–15 · Mobilize. Human capital structural integrity. Leadership readiness, succession depth, retention design, culture codification. The Pillar II work is where Transferable Value compounds.
- Months 16–18 · Endure. Pressure-test the substrate. Re-score the BRI. Confirm 85+. Go to market with quantified evidence next to the CIM.
A seller preparing for market is not preparing for a single transaction event. They are preparing for the scrutiny the evolved buyer applies before, during, and after the deal. Transparency, when structured and evidenced, builds buyer confidence and accelerates deal velocity.
Regulatory and buyer context
Regulatory environment. FDA 21 CFR 820, ISO 13485, MDR (EU), state pharmacy boards.
Active buyers in your segment. Mature. The typical buyer profile includes pe platforms (medical), strategic medtech, family offices.